Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy by Sandeman, Kevin et al.
RESEARCH ARTICLE
Prostate MRI added to CAPRA, MSKCC and
Partin cancer nomograms significantly
enhances the prediction of adverse findings
and biochemical recurrence after radical
prostatectomy
Kevin Sandeman1,2*, Juho T. EineluotoID2,3, Joona Pohjonen2, Andrew Erickson2,
Tuomas P. Kilpela¨inen3, Petrus Ja¨rvinen3, Henrikki Santti3, Anssi Petas3,
Mika Matikainen3, Suvi Marjasuo4, Anu Kentta¨mies4, Tuomas Mirtti1,2, Antti Rannikko2,3
1 Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland,
2 Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland,
3 Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland,





To determine the added value of preoperative prostate multiparametric MRI (mpMRI) sup-
plementary to clinical variables and their role in predicting post prostatectomy adverse find-
ings and biochemically recurrent cancer (BCR).
Methods
All consecutive patients treated at HUS Helsinki University Hospital with robot assisted radi-
cal prostatectomy (RALP) between 2014 and 2015 were included in the analysis. The
mpMRI data, clinical variables, histopathological characteristics, and follow-up information
were collected. Study end-points were adverse RALP findings: extraprostatic extension,
seminal vesicle invasion, lymph node involvement, and BCR. The Memorial Sloan Kettering
Cancer Center (MSKCC) nomogram, Cancer of the Prostate Risk Assessment (CAPRA)
score and the Partin score were combined with any adverse findings at mpMRI. Predictive
accuracy for adverse RALP findings by the regression models was estimated before and
after the addition of MRI results. Logistic regression, area under curve (AUC), decision
curve analyses, Kaplan-Meier survival curves and Cox proportional hazard models were
used.
Results
Preoperative mpMRI data from 387 patients were available for analysis. Clinical variables
alone, MSKCC nomogram or Partin tables were outperformed by models with mpMRI for
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the prediction of any adverse finding at RP. AUC for clinical parameters versus clinical
parameters and mpMRI variables were 0.77 versus 0.82 for any adverse finding. For
MSKCC nomogram versus MSKCC nomogram and mpMRI variables the AUCs were 0.71
and 0.78 for any adverse finding. For Partin tables versus Partin tables and mpMRI vari-
ables the AUCs were 0.62 and 0.73 for any adverse finding. In survival analysis, mpMRI-
projected adverse RP findings stratify CAPRA and MSKCC high-risk patients into groups
with distinct probability for BCR.
Conclusions
Preoperative mpMRI improves the predictive value of commonly used clinical variables for
pathological stage at RP and time to BCR. mpMRI is available for risk stratification pre-
biopsy, and should be considered as additional source of information to the standard predic-
tive nomograms.
Introduction
Prediction of prostate cancer (PC) extent and overall pretreatment risk assessment are main
challenges in everyday urological practice. In addition to the pathological Gleason Grade
Group (GGG) assessed in prostate biopsies (Bx), other variables such as age, prostate-specific
antigen (PSA), clinical stage, and biopsy-based tumor volume have been used to predict post-
operative tumor characteristics of an individual PC patient [1–5]. These variables have also
been incorporated into mathematical models to construct tools such as Partin tables, Memo-
rial Sloan Kettering Cancer Center (MSKCC) nomograms and Cancer of the Prostate Risk
Assessment (CAPRA) score [2, 3, 5] in order to improve predictions. Recently, prostate multi-
parametric magnetic resonance imaging (mpMRI) has been suggested as a tool to improve PC
diagnostics and especially of clinically significant PC [4]. Prostate Imaging Reporting and Data
System (PI-RADS) was introduced in 2012 to standardize the reporting of mpMRI findings
[6]. The use of the PI-RADS approach is based upon literature evidence and consensus expert
opinions [6]. However, only a few studies have assessed the value of mpMRI to predict adverse
pathology and biochemical recurrence (BCR) in men undergoing RP, and even fewer studies
have evaluated the added value of MRI over the pre-existing clinical variables and nomograms,
and the results have been conflicting [7–11]. Further, combination of mpMRI and predictive
nomograms in outcome assessment have not been studied in detail.
The aim of this study was to evaluate the added value of mpMRI in comparison to com-
monly used clinical variables as well as standard pre- and postoperative nomograms to predict
adverse pathology and BCR in men undergoing RP in a contemporary series utilizing PI-R-
ADS reporting system [6, 12].
Materials and methods
Patient population
A total of 598 patients underwent robot assisted laparoscopic prostatectomy (RALP) at the
HUS Helsinki University Hospital during the study period from January 2014 to September
2015. Of these, 211 (35%) patients underwent RALP without preoperative mpMRI and were
excluded from this study. Thus, the study cohort consists of 387 consecutive patients that
underwent mpMRI prior to their RALP at treating clinician’s discretion. Preoperative clinical
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and pathological data of the entire cohort were retrieved from the prospective RALP database.
These data included age, clinical stage, PSA, primary GS, secondary GS, number of positive
biopsies and total number of biopsies. These were markedly the same between the mpMRI
cohort and non-mpMRI cohort, confirming that no obvious selection bias existed for patient
referral to pre-operative mpMRI (Table 1). At the time of the data curation, we included all the
patients having undergone MRI according to contemporary guidelines and having follow-up
information in order to conduct survival analysis. Therefore, no formal power calculations
were performed but, instead, all patients during the study period were included. The data was
accessed and collected between October 2016 and June 2019 from the electronic health records
of the HUS Helsinki University Hospital. The original data was accessed based on patients’
social security numbers but in the study database all data was handled pseudonymized and
according to the study approval by the HUS Helsinki University Hospital. The study was a ret-
rospective registry study and thus no informed consent was required, based on the national
and European Union legislation. The study was conducted according to the Declaration of
Helsinki and approved by the Institutional Ethics Committee of Helsinki University Hospital
(diary number 386/13/03/02/2014).
mpMRI technique
Prostate mpMRI was performed without an endorectal coil using a 3.0 T Philips Achieva MRI
scanner, which produced 3-mm thick image slices. The modality included T2WI, DWI with
ADC mapping and DCE conforming to European Society of Urogenital Radiology guidelines
as previously described [6, 13]. The mpMRI data were interpreted by one of the four experi-
enced uroradiologists all of whom were familiar with prostate mpMRI i.e. each uroradiologist
had read over 300 prostate mpMRIs per year. At the time, mpMRI data were reported accord-
ing to PI-RADSv1 recommendations by using a structured formula as follows: number of
lesions, tumor volume and maximal diameter, PI-RADS-score, extraprostatic extension (EPE),
seminal vesicle invasion (SVI), node status (NS) and radiologic stage.
Table 1. Preoperative variables of all RALP patients with and without preoperative mpMRI.
Preoperative mpMRI No preoperative mpMRI
Result IQR or % of total Result IQR of % of total
Number of patients 387 - 211 -
Median age, yrs 65 60–69 66 61–70
Median preoperative PSA, ng/ml 9.0 6.2–13.6 8.3 3.6–9.9
Biopsy data available 384 99.2 211 100
GGG. No.
GGG1 90 23.3 46 21.8
GGG2 135 34.9 83 39.3
GGG3 105 27.1 52 24.6
GGG4 29 7.5 21 10.0
GGG5 25 6.5 9 4.3
Median prostate volume, cm3 35 27–45 - -
Median prostate weight, g 48 41–59 - -
IQR: Interquartile Range, GGG: Gleason Grade Group
https://doi.org/10.1371/journal.pone.0235779.t001
PLOS ONE MRI and nomograms on risk stratification of prostate cancer patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0235779 July 9, 2020 3 / 14
Prostatectomy specimen and pathologic analysis
RALP was performed transperitoneally and the indication for extended lymphadenectomy
was GS�4+3 or >5% risk of lymph node positive disease according to the Memorial Sloan
Kettering nomogram [2, 14]. The prostate specimens and lymph nodes were processed as
described earlier [15]. All prostate material was completely mounted. Lymphadenectomy spec-
imens were mounted per localization. The original pathological diagnosis was made individu-
ally by 12 expert pathologists, out of which 4 reported 80% of the cases. Pathological
anatomical diagnosis (PAD) report of RALP specimen including primary and secondary GS,
tumor volume, margin status, EPE, SVI, NS and pathologic stage (pT) was collected from the
RALP database [16]. Adverse pathologic findings were defined as EPE, SVI or positive NS.
Statistical analyses
Multivariable logistic regression models were used to study the relationship between adverse
RP findings (EPE, SVI or positive NS) and clinical variables available before RALP (preopera-
tive PSA, age, cT-stage, percentage of positive biopsy cores, GGG), MSKCC preoperative
nomogram and Partin Table estimates. Cox proportional hazards models and Kaplan-Meier
survival curves were generated for clinical variables, CAPRA score and MSKCC nomogram
parameters in predicting BCR. All models were compiled following the purposeful selection of
covariates [17, 18]. Next, available mpMRI variables assessing EPE, SVI or positive NS, pros-
tate volume and PI-RADS score were added to the models. The final models with and without
the mpMRI variables were compared by decision curve analysis [19], area under the receiver
operating characteristics (ROC) curve and multiparametric Wald test. Eighty-one patients had
missing values for positive and total biopsy cores and these were imputed using multiple impu-
tation by chained equations [20]. An alpha level of 0.05 was used for statistical significance. All
statistical analyses were performed with R Statistical Software v.3.6.1 [21] using the packages:
survival [22], precrec [23], mfp and mice[20].
Results
Cohort
Of the 387 mpMRI patients with a median age of 65 years at RALP, preoperative PSA and
diagnostic biopsy data were available for 384 patients (Table 1). Distribution of mpMRI, clini-
cal and pathological staging as well as PI-RADS scores and RP GGG are presented in S1 Table.
The number of patients in each subcohort in the regression models and survival analyses are
presented in S1 Fig. As Partin tables do not include cT3, patients with clinical T3 were
excluded from the analysis concerning Partin tables. Similarly, as CAPRA is designed to pre-
dict BCR, it was omitted from the regression models for adverse RP findings.
Predicting adverse findings at RP (Partin, MSKCC, clinical variables,
mpMRI)
Results of the multivariable logistic regression models for any RP adverse findings are shown
in Table 2. Values were dichotomized for clinical stage (<cT2 versus�cT3), GGG (<2 versus
�3) and PIRADS score (<2 versus�3). From all considered clinical covariates, age was not
significantly associated with any adverse finding. However, based on the known effect to PC
risk, age was left in to the model. From mpMRI variables, prostate volume was not significantly
associated with any adverse RP finding. All models with mpMRI variables were significantly
different from models with clinical variables only based on the multiparametric Wald test (p-
values< 0.001). From the preoperative clinical variables, cT-stage� 3 had the highest odds
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ratio of 3.98. In addition, The MSKCC nomogram and Partin Table risk predictions were sig-
nificantly associated with any adverse RP finding (p< 0.001) with respective odds ratios of
1.05 and 1.03 (1% increase in risk score). In the ROC-AUC analyses, when mpMRI was added
to the other models (clinical variables, Partin parameters and MSKCC estimates), all combined
models outperformed the individual models without mpMRI. The decision curve analysis
showed a net benefit for all models combined with mpMRI for patients with a threshold prob-
ability between approximately 10 to 15 and 55 to 75% for any adverse finding (Fig 1A–1F).
BCR free survival (CAPRA, MSKCC, clinical variables, mpMRI)
Kaplan-Meier survival plots revealed that all preoperative clinical variables and mpMRI indi-
cating adverse RP findings separate the patient cohort into two groups with different survival
probability (for all variables p< 0.01 in log rank test, S2A–S2F Fig). Neither mpMRI prostate
volume (> 35 cc) nor the PIRADS score higher than two separated the groups significantly
(S3A and S3B Fig).
Table 2. Regression model summaries: Prediction of any adverse findings at prostatectomy.
Model without mpMRI parameters Model with mpMRI parameters
Estimate OR (95% CI) p value Estimate OR (95% CI) p value
MRI
- - - - MRI ANY 1.420 4.14 (2.641–6.481) <0.001
- - - - PI-RADS� 3 1.218 3.40 (1.249–9.149) 0.017
- - - - MRI prostate volume -0.013 0.99 (0.972–1.003) 0.095
PARTIN PARTIN + MRI
Partin ANY 0.026 1.03 (1.012–1.041) <0.001 Partin ANY 0.025 1.03 (1.011–1.039) <0.001
- - - - MRI ANY 1.277 3.59 (2.116–6.075) <0.001
- - - - PI-RADS� 3 0.837 2.31 (0.83–6.425) 0.110
- - - - MRI prostate volume -0.010 0.99 (0.973–1.008) 0.235
MSKCC MSKCC + MRI
MSKCC ANY 0.053 1.05 (1.04–1.069) <0.001 MSKCC ANY 0.045 1.05 (1.03–1.063) <0.001
- - - - MRI ANY 1.139 3.12 (1.944–5.019) <0.001
- - - - PI-RADS� 3 1.090 2.97 (1.071–8.258) 0.037
- - - - MRI prostate volume -0.017 0.98 (0.968–0.999) 0.042
CLINICAL CLINICAL + MRI
PSAPre 0.041 1.04 (1.012–1.073) 0.008 PSAPre 0.052 1.05 (1.017–1.091) 0.003
Age 0.036 1.04 (0.999–1.076) 0.059 Age 0.144 1.16 (1.033–1.291) 0.011
GGG� 3 0.508 1.67 (1.028–2.686) 0.039 GGG� 3 0.521 1.68 (1.006–2.819) 0.048
Positive Bx(%) 0.024 1.02 (1.012–1.036) <0.001 % positive biopsies 0.022 1.02 (1.01–1.034) <0.001
cT� 3 1.382 3.98 (2.029–7.817) <0.001 cT� 3 given MRI ANY 2.047 7.74 (1.868–32.093) 0.005
- - - - cT� 3 given MRI OC 0.426 1.53 (0.659–3.56) 0.323
- - - - MRI ANY given cT� 3 1.218 3.38 (1.939–5.893) <0.001
- - - - MRI ANY given cT < 3 -0.403 0.67 (0.14–3.187) 0.614
- - - - PI-RADS� 3 1.104 3.02 (0.985–9.236) 0.054
- - - - MRI prostate volume 0.184 1.20 (1.002–1.442) 0.049
- - - - Age x MRI prostate vol. -0.003 0.033
- - - - cT� 3 x MRI ANY -1.621 0.056
MRI: magnetic resonance imaging; ANY: suggestion of extraprostatic extension, seminal vesicle invasion or lymph node involvement; OC: organ-confined (�pT2); cT:
clinical stage
https://doi.org/10.1371/journal.pone.0235779.t002
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In the Kaplan-Meier analysis, CAPRA risk score separated the patients into three distinct
groups (Fig 2A–2C). In the CAPRA dataset, the time for BCR was significantly shorter when
the mpMRI indicates adverse RP findings, than for the patients with favorable mpMRI find-
ings. Additionally, for the high risk CAPRA group, mpMRI adverse findings separates the
patients into two groups with significantly different survival times. In the intermediate
CAPRA risk group, there were no differences in the survival times based on mpMRI findings
(S4 Fig). For the low risk groups, there were only two events, thus no comparisons could be
made.
When we looked at the MSKCC 3-year survival probability, a cut-off value of 80% signifi-
cantly separated the patients into two groups with different survival probabilities (Fig 3A). In
the high risk group, the mpMRI for any adverse RP finding significantly added value, separat-
ing the group into two cohorts with significantly different survival curves (Fig 3B). In the low
risk MSKCC group there were no differences in the survival times based on mpMRI findings
(S5 Fig).
As a positive surgical margin is a strong predictor of BCR all survival analyses were also
done by excluding patients with a positive surgical margin [24]. All described results remained
significant except for patient age (> 65 years), where the p-value increased to 0.633.
The cox proportional hazard models showed that mpMRI features associating with adverse
RP findings correlate with BCR in an univariate model (S2 Table). However, when comparing
models with and without the mpMRI indicating for adverse RP findings, no significant differ-
ences between the models were observed in the multivariable Wald test.
Discussion
Here, we have addressed the value of combining mpMRI with clinical parameters, MSKCC
nomogram and Partin nomogram to predict EPE, SVI or NS as adverse findings in RP in a
contemporary cohort of PC patients. We can conclude that mpMRI improves the prediction
of adverse pathology at RP when added to traditional preoperative prediction tools over a wide
range of decision thresholds. Furthermore, mpMRI significantly added to the prediction of
BCR when combined with the commonly used predictive tools CAPRA and MSKCC
nomograms.
Our results on mpMRI-based prediction of adverse pathology at RALP are mostly in con-
cordance with the literature. In a meta-analysis by de Rooij et al., a total of 75 studies (9796
patients) were analyzed and pooled for EPE (45 studies, 5681 patients), SVI (34 studies, 5677
patients), and overall stage T3 detection (38 studies, 4001 patients). The analysis for MRI
found sensitivities and specificities for EPE, SVI and overall stage T3 detection of 0.57 and
0.91; 0.58 and 0.96; and 0.61 and 0.88, respectively. Functional imaging in addition to
T2-weighted imaging and use of higher field strengths (3T) improved sensitivity for EPE and
SVI. However, the heterogeneity of the studies included in the meta-analysis and the variability
of the reported techniques (including pre PI-RADS era studies) hamper the interpretation of
the results [25].
Recently, Morlacco et al. similarly evaluated the incremental value of MRI in a pre PI-RADS
era (2003 to 2013) prostatectomy cohort [7]. The authors evaluated 914 patients with preoper-
ative MRI of which 501 patients with endorectal coil MRI were eventually included in their
analysis. They conclude that MRI provides added staging value and they also speculate that the
inherent limitations in their study (pre PI-RADS era and high-risk patient cohort) may
Fig 1. Additive predictive value of any adverse RP findings by mpMRI in ROC-AUC and Decision curve analysis (DCA) for a-b)
clinical characteristics; c-d) Partin table estimates; e-f) MSKCC nomogram parameters.
https://doi.org/10.1371/journal.pone.0235779.g001
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actually underestimate the added value of MRI. Our results suggest added value for MRI as a
staging tool in the PI-RADS era. The study cohorts are relatively similar in respect to the risk
factors (e.g.�pT3 49% vs 44%) but they substantially differ in MRI technique used (1.5T MRI
and endorectal coil versus 3T pelvic coil and non-structured vs structured reporting). Further-
more, it is not possible to analyze the extent of selection bias in the Morlacco study as they did
not report the characteristics of the cohort that did not undergo MRI [7]. Thus, one may spec-
ulate that clinical decision making was skewed towards guiding patients to MRI that were
more likely to benefit from it. In addition to the AUC analysis, our decision curve analysis data
suggested that the added net benefit for MRI extends over a wide range of threshold probabili-
ties for EPE and SVI. Interestingly, another cohort with endorectal coil and no PI-RADS
reported added value of preoperative MRI for staging of SVI [12]. The authors of that study
reported significantly higher AUC values for Partin residues to predict SVI with and without
MRI of 0.84 and 0.93, respectively, when compared to our data (0.68 and 0.73, respectively),
suggesting different background risk in the two cohorts.
Gupta et al [26] addressed the accuracy of mpMRI and Partin Tables to predict EPE, but
did not analyze the added value of mpMRI. In their analysis of only 60 patients, the ability of
Partin Tables to predict EPE was comparable to ours (AUC of 0.62 vs 0.56). The mpMRI in
their analysis, on the other hand, was a clearly better predictor of EPE than in our analysis
(AUC of 0.82 vs 0.62). Significantly better predictive improvements have also been reported
for MRI, when added to the Partin clinical model. In a subsequent study in 2016 Gupta et al
found no added benefit of substituting multiparametric MRI stage for clinical stage (AUC of
0.63) to define organ-confined (OC) disease when using Partin tables (AUC of 0.70), while
mpMRI was valuable as a stand-alone staging test (AUC 0.88) [27]. AUCs reported by Feng
et al. for Partin and MSKCC nomograms predicting EPE were 0.85 and 0.86 and increased to
0.92 and 0.94, respectively, when mpMRI was added to each nomogram [28]. The Feng et al.
and Gupta et al. studies relied on only one radiologist in their respective protocols to report
the MRI results, which diminishes the effect of interreader variability in the results of both
studies [26–28].
Our data suggests that when added to well-known prediction tools, prostate mpMRI aids in
predicting BCR after RP, as it supports a more specific classification within the high risk
CAPRA and MSKCC groups. Even as a standalone investigation, mpMRI was able to separate
two groups with distinct BCR survival. Our results are in concordance with a small pre-PI-R-
ADS era study where the ability of mpMRI to predict BCR after RP was seen, while the added
value to CAPRA or MSKCC was not assessed [29]. As mpMRI is in part a surrogate method to
predict RP findings, standardization of mpMRI reporting is expected to further improve its
predictive value, as it is well known that adverse RP findings can predict BCR.
PI-RADS version 1 was the recommended reporting platform at the time of our study.
PI-RADS version 2 or 2.1 may improve the inter-observer variability and diagnostic reliability
[30]. Instead of a more recent PIRADS 2/2.1 cohort, we chose to analyze a PIRADS 1 cohort
with longer follow-up time, which allowed us to use BCR as a study end point. The experience
of the four radiologists in our study may be advantageous in diminishing inter-observer vari-
ability, especially for tumors in the peripheral zone as these are less dependent on the PI-RADS
[31].
Fig 2. BCR free survival probability–a) Kaplan-Meier survival analysis for CAPRA risk groups; b) Survival plots for
mpMRI any adverse finding (ANY) versus organ confined (OC) in the CAPRA group; c) Survival plot for mpMRI any
adverse finding (ANY) versus organ confined (OC) in the CAPRA high risk group.
https://doi.org/10.1371/journal.pone.0235779.g002
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Taken together, the evidence in the current literature tend to support the use of preopera-
tive MRI as a staging tool, especially in regard to EPE and SVI. Despite the uncertainty of
exactly predicting the presence of EPE or SVI, all the information combined, i.e. the size and
location of the tumor among many other MRI and clinical variables may influence preopera-
tive decision making and planning of the surgical procedure. This was recently shown in a ret-
rospective cohort in which patients that had preoperative MRI were more likely to undergo
non-nervesparing RP and had lower likelihood of positive surgical margins [24].
While the literature and the results by us may support the role of MRI as a staging tool for
EPE and SVI preoperatively, the case is less clear for nodal status where a pooled sensitivity of
only 0.39 has been reported [32]. A significant proportion of lymph node metastases are
microscopic and enlarged lymph nodes may be reactive thereby hampering the size criterion
in nodal status evaluation with any imaging modality, including MRI. Contrary to our results,
recently a nomogram incorporating MRI has been developed to predict nodal status before RP
[33]. This nomogram does not rely on the evaluation of the nodal status per se by MRI (con-
trary to our analysis). Instead, several MRI related variables are added to the existing model.
This further supports the use of MRI preoperatively despite the actual evaluation of nodal sta-
tus seems to be suboptimal with the current MRI techniques.
The limitations of our study include retrospective analysis of single center data. Selection
bias cannot be ruled out as not all patients had preoperative MRI during the study period.
However, no obvious differences where noted when we compared the demographics of these
groups. Furthermore, in order to enhance diagnostic accuracy, to improve translational PC
research and to better integrate MRI with pathology and to support clinical decision making,
pathologists are encouraged to adopt regional reporting system similar to the PI-RADS [34].
Preoperative prostate MRI adds to prediction of adverse findings at RP and BCR after RP.
As mpMRI is more commonly used for risk stratification at prebiopsy setting, mpMRI param-
eters are becoming more readily available and should be considered as additional source of
information to the standard predictive nomograms.
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S1 Table. a) Comparison of mpMRI, clinical and pathological staging. Distribution of lymph
node finding; 1 b) Distribution of PI-RADS and prostatectomy grading. PI-RADS score in
multiparametric MRI and Gleason Grade Group in surgical specimen for ROI1.
(DOCX)
S2 Table. Cox proportional hazard model summaries: prediction of biochemical recur-
rence.
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S1 Fig. Flowchart for the analyses. LND: Lymph node dissection. CAPRA = Cancer of the
Prostate Risk Assessment; MRI = magnetic resonance imaging.
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S2 Fig. BCR free survival probability–Kaplan-Meier survival analysis for clinical parameters:
a) clinical T-stage equal or higher than 3 (follow-up data for clinical T-stage missing for one
patient); b) Gleason Grade Group equal or higher than 3; c) preoperative PSA equal or higher
than 10 μg/l; d) percentage of positive biopsies equal or higher than 50%; e) MRI prediction
Fig 3. BCR free survival probability–a) Kaplan-Meier survival analysis for MSKCC BCR free survival at 80% after 3
years; b) Survival plot for mpMRI any adverse finding (ANY) versus organ confined (OC) in the MSKCC BCR high risk
group (<80%).
https://doi.org/10.1371/journal.pone.0235779.g003
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S3 Fig. BCR free survival probability–Kaplan-Meier survival analysis for clinical parameters:
a) mpMRI prostate volume (> 35 cc); b) PI-RADS score higher than two.
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S4 Fig. BCR free survival probability–Kaplan-Meier survival analysis for intermediate
CAPRA risk group.
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